Fundraising Fox

Umoja Biopharma, Inc.

Seattle, US · Founded 2019 · Delaware corporation · 5 known investors

umoja-biopharma.com ↗

Umoja Biopharma develops in vivo CAR T cell therapies for cancer treatment using its VivoVec platform, which generates CAR T cells directly in patients' bodies. The company operates its own manufacturing facility to produce these cancer immunotherapies.

BiotechDigital HealthMedical Devicesin /umoja-biopharma@UmojaBiopharma

Founders & leadership

PS
Philip S. LowDirector
IM
Irena MelnikovaExecutive Officer
AF
Anna FrenchDirector
RG
Robert GlassmanDirector
JH
John HamerDirector
LE
Luke EvninDirector
AM
Andrew M. ScharenbergExecutive Officer, Director

Investors · 5

K2 HealthVenturesBoston · $10M – $100M
MPM BioImpactBoston · $1M – $15M
MPM Capitalvia Luke Evnin · board
DCVC (Data Collective)reportedPalo Alto · $5M – $25M
DCVC Bioreported · 2 sourcesPalo Alto

Reported raises · per SEC filings

Form D private placements
▶$210MraisedJun 2021 · 29 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Philip S. LowDirector
  • Irena MelnikovaExecutive Officer
  • Anna FrenchDirector
  • Robert GlassmanDirector
  • John HamerDirector
  • Luke EvninDirector
  • Andrew M. ScharenbergExecutive Officer, Director
Offering amount
$210M
Amount sold
$210M
First sale
Jun 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news